Multidrug-resistant TB in Eastern region of the EU: is the shorter regimen an exception or a rule?
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 28209653.
- Also identified by DOI 10.1136/thoraxjnl-2016-209841.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
WHO recently recommended the use of a shorter multidrug-resistant TB (MDR-TB) regimen under programmatic conditions. We assessed eligibility for this regimen in a cohort of 737 adult patients with MDR-TB from Latvia, Lithuania, Estonia and Bucharest city recruited in 2007 and 2009. Only 4.2% of the patients were eligible for this regimen. Ethambutol (64%), pyrazinamide resistance (58%) and previous exposure to second-line TB drugs were major reasons for non-eligibility. High-level resistance to isoniazid is expected due to widespread prevalence of <i>katG</i> mutations. In Eastern Europe, the use of the shorter regimen might be an exception rather than a rule.
Medical subject headings
- Antitubercular Agents
- Tuberculosis, Multidrug-Resistant